Zhongguancun announced that the “National Essential Drug Catalogue” came into effect on September 1. Fourteen of the company's subsidiaries have been included in the catalogue. This time, 4 new varieties have been added and 1 variety has been withdrawn. Sales revenue of the company's strategic product oxycodone hydrochloride injection increased 121.95% year-on-year in 2025, and its entry into the “Basic Drug Catalogue” will strengthen the company's advantage. The introduction of new products will help expand coverage and is expected to have a positive impact on long-term development, but drug sales are affected by various factors, and there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.